erlotinib hydrochloride has been researched along with ku 0063794 in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (ku 0063794) | Trials (ku 0063794) | Recent Studies (post-2010) (ku 0063794) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 55 | 0 | 52 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | ku 0063794 (IC50) |
|---|---|---|---|
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | Homo sapiens (human) | 5.3 | |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | Homo sapiens (human) | 8.9 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.1182 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 8.3 | |
| Rapamycin-insensitive companion of mTOR | Homo sapiens (human) | 0.01 | |
| Regulatory-associated protein of mTOR | Homo sapiens (human) | 0.335 | |
| Target of rapamycin complex 2 subunit MAPKAP1 | Homo sapiens (human) | 0.01 | |
| Target of rapamycin complex subunit LST8 | Homo sapiens (human) | 0.2267 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| An, Z; Fan, QW; Haas-Kogan, DA; Lu, M; Luo, X; Phillips, JJ; Shokat, KM; Weiss, WA; Wong, RA | 1 |
1 other study(ies) available for erlotinib hydrochloride and ku 0063794
| Article | Year |
|---|---|
Cooperative Blockade of PKCĪ± and JAK2 Drives Apoptosis in Glioblastoma.
Topics: Acrylamides; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Indoles; Janus Kinase 2; Mice; Morpholines; Protein Kinase C-alpha; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2020 |